XBIT SEC Filings: 8-K, 10-Q, S-3 & 424B – XBiotech

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K/A

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Apr 29, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

XBiotech Appoints Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers

Oct 26, 2026

8-K

XBiotech Announces Interim CEO Transition as John Simard to Retire; Sushma Shivaswamy Named Interim CEO and CSO

Dec 9, 2025

8-K/A

Clarification on Director's Role at Canadian Private Equity Firms Provided

Oct 15, 2025

8-K

XBiotech Inc. Enters into New Executive Employment Agreement with John Simard

Oct 3, 2025

8-K

XBiotech Inc. Annual Meeting Results

Sep 2, 2025

8-K

XBiotech Inc. Appoints New Board Members

Jun 24, 2025

Prospectus

TYPE

HEADLINE

FILED AT

424B5

SHELF OFFERING | Shares amount: 4,848,485 | Share price: $8.25 | Offering amount: $40,000,001.00 | Bank: Piper Jaffray

Jun 3, 2019

424B5

PENDING OFFERING | Bank: Piper Jaffray

May 30, 2019

424B5

ATM

May 1, 2019

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Mar 3, 2017

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Sep 26, 2016

424B4

Form 424B4 - Prospectus [Rule 424(b)(4)]

Apr 16, 2015

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 11, 2026

SC TO-I/A

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Jun 20, 2023

SC TO-I

Form SC TO-I - Tender offer statement by Issuer

May 17, 2023

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Oct 2, 2020

SC TO-I/A

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Feb 19, 2020

SC TO-I/A

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Feb 13, 2020

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Oct 2, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jul 7, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 1, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

May 1, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2023

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2023

Ownerships

TYPE

HEADLINE

FILED AT

Simard Jan-Paul (Reporting)

Oct 28, 2026

Simard Jan-Paul (Reporting)

Oct 28, 2026

SIMARD JOHN (Reporting)

Oct 28, 2026

SCHEDULE 13G/A

MCKENZIE W THORPE (Filed by)

Jan 23, 2026

SCHEDULE 13G/A

SIMARD JOHN (Filed by)

Jan 23, 2026

Rademaker Craig Evan (Reporting)

Nov 12, 2025

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Oct 1, 2018

CORRESP

Form CORRESP - Correspondence

Sep 4, 2018

LETTER

Form UPLOAD - SEC-generated letter

Aug 6, 2018

CORRESP

Form CORRESP - Correspondence

Jul 31, 2018

LETTER

Form UPLOAD - SEC-generated letter

Jul 24, 2018

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 2, 2016

XBiotech Inc. XBIT · SEC Filings